热门资讯> 正文

United Therapeutics和Intermountain Health宣布，世界上第一例接受生物工程外部肝脏辅助产品miroliverEurs临床研究的患者接受治疗

2025-06-24 19:08

This study is the first human clinical trial of a manufactured organ alternative.
The procedure was performed on a patient experiencing liver failure who was not eligible for a liver transplant. The procedure was performed by the team at Intermountain Medical Center in Murray, Utah, led by Christopher J. Danford, MD, a transplant hepatologist at Intermountain Health.
Developed by Miromatrix Medical Inc., a United Therapeutics subsidiary, miroliverELAP is an external liver assist combination product consisting of a single-use MIRO-001 bioengineered liver and an extracorporeal blood circuit.
The bioengineered liver is made up of a decellularized porcine liver scaffold to which allogeneic3 human endothelial4 and liver cells have been added.
"This first of its kind treatment represents a historic achievement for United Therapeutics and Miromatrix in advancing the potential of bioengineered human organs to help save and improve patients' lives," said Jeff Ross, Ph.D.,President of Miromatrix. "We're grateful to the patient and their family, in addition to the scientists and caregivers at Intermountain Health and Intermountain Medical Center who helped make this breakthrough possible. Looking ahead, we're excited to continue progressing our ongoing phase 1 clinical trial."
"This groundbreaking procedure – the first of its kind in the world – represents everything Intermountain Health stands for in providing innovative, cutting-edge high-quality care for our patients," said Ralph Jean-Mary, president of Intermountain Medical Center. "We are profoundly thankful to this patient for their participation in this pioneering study, and to our exceptional Intermountain medical team, as well as our partners at United Therapeutics and Miromatrix. This procedure reinforces our unwavering commitment to leading in clinical excellence and helping people live the healthiest lives possible."
United Therapeutics' organ and organ alternative manufacturing efforts consist of three platforms – xenotransplantation,5 allogeneic regenerative medicine, and autologous6 regenerative medicine – encompassing four different organs: hearts, kidneys, livers, and lungs. These revolutionary programs are intended to address the ongoing shortage of transplantable organs for patients with end-stage organ disease.
The investigational miroliverELAP system is not approved for any use in any country.

United Therapeutics和Intermountain Health宣布，世界上第一例接受生物工程外部肝脏辅助产品miroliverEurs临床研究的患者接受治疗

推荐文章

美股机会日报 | 特朗普放大招！9万亿养老金即将杀入加密市场；美联储主席候选人支持7月降息

一周财经日历 | 特斯拉、谷歌财报重磅来袭！维立志博将于下周五登陆港交所

一图看懂 | 港股上半年IPO募资额登顶全球！中签就赚一万港币的“大肉签”你参与了吗？

华盛早报丨重大突破！三大加密货币法案众议院闯关成功；美联储，降息大消息

黄仁勋年内三度访华！H20重返中国市场，释放了什么信号？

创新药行情彻底爆发！维立志博-B打新半日孖展超购130倍，冻资近150亿港元

新股申购 | 维立志博-B入场费3535.30港元！引入腾讯、易方达等基石投资者

7月财报预告丨迎关税考验！特斯拉、台积电放榜在即，美股能否守住涨势？